Stamulumab

drugbox-mab


source = Human
target =
CAS_number = 705287-60-1
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
C=6330 | H=9748 | N=1672 | O=1668 | S=48
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = injection only

Stamulumab (MYO-029 [http://www.wyeth.com/research/pipeline Wyeth Product Pipeline] , Wyeth, Website accessed April 22, 2007] ) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy. MYO-029 was formulated and tested by Wyeth in Collegeville, Pennsylvania.NIH's ClinicalTrials.gov, [http://www.clinicaltrials.gov/ct/show/NCT00104078?order=6 Study Evaluating MYO-029 in Adult Muscular Dystrophy] , record last updated January 24, 2007] Myostatin is a protein that inhibits the growth of muscle tissue, MYO-029 is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. [medicalnewstoday.com, [http://www.medicalnewstoday.com/medicalnews.php?newsid=20441 Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029] , Article Date: 28 Feb 2005 - 7:00 PDT]

Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy [http://www.mdausa.org/news/021127micedmd.html Blocking Myostatin Proves Beneficial in Mice with DMD] , MDA Research News, 11/27/2002]

Phase 1 and 2 Trials

*Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of MY0-029. The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy. The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy. Through 2007 Wyeth has been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur. [http://www.mda.org/research/061204myo_029_nov06.html Wyeth Analyzing MYO-029 Results] , Muscular Dystrophy Association announcement, December 4, 2006] [http://www.fshsociety.org/fsh/FSHSociety_FSHWatchNewsletterSummer2007.pdf FSH Watch Newsletter] , pg 11, FSH Society, Summer 2007] . However, as of January 24, 2008, the study has been accepted by a peer-reviewed journal and publication is expected "in the next few months" [http://blog.wired.com/wiredscience/2008/01/pharma-company.html Pharma Company Responds to WiSci on Muscle-Building Drug] , Wired Science, Alexis Madrigal, January 24, 2008, 2008, 4:26:27 PM]

Related

* ACVR2B is similar to Stamulumab but is not an antibody; rather, it provides a portion of the molecule to which myostatin would normally bind thus preventing the myostatin from binding with the actual molecule [http://www.mdausa.org/research/060106myostatin_blocker.html New Myostatin Blocker Makes Mouse Muscles 60 Percent Larger] , MDA Research News, January 6, 2006] .

References